GANAB

Across TCGA pan-cancer cohorts, GANAB Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GANAB data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher GANAB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GANAB expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

MESO, UCEC, and PRAD are the cancer types where GANAB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	III,IV	0.082	0.414	.007	18	view →
UCEC	DFS	Median	All	0.968	0.621	.007	16	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LGG	OS	Median	All	0.250	0.830	.001	6	view →
LUAD	DFS	Median	II,III,IV	0.098	0.651	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GANAB–MESO (DFS)

Open the MESO breakdown →